The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study.

Journal: Clinical lymphoma, myeloma & leukemia
PMID: 29429612

Abstract

BACKGROUND: The phase III MDS-005 study compared lenalidomide versus placebo in red blood cell transfusion-dependent (RBC-TD) patients with lower-risk non-del(5q) myelodysplastic syndromes (MDS), ineligible/refractory to erythropoiesis-stimulating agents. Lenalidomide-treated patients were more likely to achieve transfusion independence (TI) ≥ 8 weeks (26.9% vs. 2.5%; P < .001) and hemoglobin increase ≥ 1.5 g/dL (19.4% vs. 2.5%) versus placebo.

Authors

  • Valeria Santini
    AOU Careggi, University of Florence, Florence, Italy. Electronic address: valeria.santini@unifi.it.
  • Antonio Almeida
    Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal.
  • Aristoteles Giagounidis
    Marien Hospital Düsseldorf, Düsseldorf, Germany.
  • Uwe Platzbecker
    Medical Clinic and Polyclinic I, University Hospital, Technical University Dresden, Dresden, Germany.
  • Rena Buckstein
    Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
  • C L Beach
    Celgene Corporation, Summit, NJ.
  • Shien Guo
    Evidera, Waltham, MA.
  • Arman Altincatal
    Evidera, Waltham, MA.
  • Chengqing Wu
    Celgene Corporation, Summit, NJ.
  • Pierre Fenaux
    Service d'Hématologie Séniors, Hôpital Saint-Louis, Université Paris 7, Paris, France.

Keywords

External Resources

Popular Topics
Recent Journals